WuXi Biologics subsidiary WuXi Vaccines has agreed to sell its vaccine manufacturing facility in Dundalk, Ireland, to MSD for approximately $500m. Expected to close in the first half of 2025, the deal ...

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global uncertainties.

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

WuXi Biologics employees have once again exemplified their deep-rooted commitment to the local community, delivering impactful support to St. Vincent de Paul Dundalk through their fourth annual ...

WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Wuxi Biologics (Cayman) ( (HK:2269) ) has provided an announcement.

The Chinese contract drugmaker will sell its vaccine factory in Dundalk, Ireland, to U.S.-based Merck for about $500 million, it said in an exchange filing late Monday. The facility, with a net ...

WuXi Biologics subsidiary WuXi Vaccines has agreed to sell its vaccine manufacturing facility in Dundalk, Ireland, to MSD for approximately $500m. Expected to close in the first half of 2025 ...

WuXi Biologics Cayman Inc. will sell a vaccine ... while continuing to navigate geopolitical tensions. The site at Dundalk, Ireland, which has been under construction since 2019, was designed ...